A randomized double-blind placebo controlled trial to evaluate the safety and efficacy of the cholesterol absorption inhibitor, ezetimibe in a dosage of 10 mg, on plasma lipids, plant sterols and inflammatory markers in children with familial hypercholesterolemia.

Trial Profile

A randomized double-blind placebo controlled trial to evaluate the safety and efficacy of the cholesterol absorption inhibitor, ezetimibe in a dosage of 10 mg, on plasma lipids, plant sterols and inflammatory markers in children with familial hypercholesterolemia.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2009

At a glance

  • Drugs Ezetimibe (Primary)
  • Indications Hyperlipoproteinaemia type II
  • Focus Biomarker; Therapeutic Use
  • Acronyms EZKIMO
  • Most Recent Events

    • 10 Dec 2009 New source identified and integrated (Netherlands Trial Register, NTR650).
    • 07 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top